
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics is poised for strong growth with the successful launch of Zelsuvmi, a new at-home treatment for molluscum contagiosum. This product is expected to generate significant revenue for the company and gain market share through pediatricians. With additional approved products and a promising pipeline, Pelthos has the potential to gain a larger market share and provide a strong return on investment. However, investors should closely monitor commercial execution and partnerships, which could pose potential risks.
Bears say
Pelthos Therapeutics is showing strong performance, with accelerating momentum and positive feedback on its Zelsuvmi product. The company's differentiated nitric oxide platform and high barriers to entry provide a competitive advantage, especially in the ocular pain market. However, there are potential risks to consider, such as regulatory and financing risks, and potential competition from other products targeting similar indications. Further success in clinical trials and securing reimbursement will be key factors in the company's future success.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares